Sugi Predict

Sugi Predict / Compounds / SCHEMBL15748622

SCHEMBL15748622

SCHEMBL15748622

Nc1ccc(-c2nnc(-c3ccc(N)cc3)c3c2CCCCCC3)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 4/20 0.40
▸ ALDH1A1 P00352 4/20 0.40
▸ TDP1 Q9NUW8 2/20 0.40
▸ TP53 P04637 1/20 0.40
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ HRH2 P25021 1/20 0.38
▸ HRH3 Q9Y5N1 1/20 0.38
▸ PTGS2 P35354 3/20 0.36
▸ ACHE P22303 1/20 0.35
▸ TAAR1 Q96RJ0 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ MEN1 O00255 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ NOS3 P29474 1/20 0.34
▸ NOS1 P29475 1/20 0.34
▸ NOS2 P35228 1/20 0.34
▸ CYP17A1 P05093 1/20 0.34
▸ CYP19A1 P11511 1/20 0.34
▸ CYP11B1 P15538 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17694188 0.93 HSD17B10 (0.48) CYP3A4ALDH1A1TDP1NPC1RAB9A
SCHEMBL17694198 0.79 MAPT (0.43) ALDH1A1TP53NPC1RAB9APTGS2
SCHEMBL4094970 0.78 PTGS2 (0.51) ALDH1A1NPC1RAB9APTGS2MEN1
SCHEMBL18137230 0.78 PTGS2 (0.51) ALDH1A1NPC1RAB9APTGS2MEN1
SCHEMBL17694190 0.77 MAOA (0.48) ALDH1A1PTGS2MEN1KMT2AMAPT
SCHEMBL23207479 0.76 HRH2 (0.43) HRH2HRH3ACHEKDM4E
SCHEMBL3701615 0.73 PARP1 (0.58) MAPTPDGFRBKITHPGD
Benzidine SCHEMBL6734146 0.71 ALDH1A1 (0.79) CYP3A4ALDH1A1TDP1TP53NPC1
Benzidine SCHEMBL28396761 0.71 ALDH1A1 (0.79) CYP3A4ALDH1A1TDP1TP53NPC1
SCHEMBL1176222 0.70 ALDH1A1 (0.50) CYP3A4ALDH1A1TDP1TP53NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11857636-B2 Bio-orthogonal drug activation TAGWORKS PHARMACEUTICALS B.V. (NL) 2024-01-02 — — US disclosed
US-11857636-B2 Bio-orthogonal drug activation TAGWORKS PHARMACEUTICALS B.V. (NL) 2024-01-02 — — US disclosed
EP-4245744-A2 CHEMICALLY CLEAVABLE GROUP Tagworks Pharmaceuticals B.V. (NL) 2023-09-20 — — EP disclosed
EP-2922574-B1 CHEMICALLY CLEAVABLE GROUP TAGWORKS PHARMACEUTICALS B V (NL) 2023-05-17 — — EP disclosed
EP-2709667-B1 BIO-ORTHOGONAL DRUG ACTIVATION TAGWORKS PHARMACEUTICALS B V (NL) 2022-04-13 — — EP disclosed
EP-3973993-A1 BIO-ORTHOGONAL DRUG ACTIVATION Tagworks Pharmaceuticals B.V. (NL) 2022-03-30 — — EP disclosed
US-20210162060-A1 BIO-ORTHOGONAL DRUG ACTIVATION TAGWORKS PHARMACEUTICALS B.V. (NL) 2021-06-03 — — US disclosed
US-10967069-B2 Bio-orthogonal drug activation TAGWORKS PHARMACEUTICALS B.V. (NL) 2021-04-06 — — US disclosed
US-20190336612-A1 BIO-ORTHOGONAL DRUG ACTIVATION TAGWORKS PHARMACEUTICALS B.V. (NL) 2019-11-07 — — US disclosed
US-10376594-B2 Bio-orthogonal drug activation TAGWORKS PHARMACEUTICALS B.V. (NL) 2019-08-13 — — US disclosed
US-9421274-B2 Bio-orthogonal drug activation KONINKLIJKE PHILIPS N.V. (NL) 2016-08-23 — — US disclosed
US-20160106859-A1 BIO-ORTHOGONAL DRUG ACTIVATION TAGWORKS PHARMACEUTICALS B.V. (NL) 2016-04-21 — — US disclosed
US-20160106859-A1 BIO-ORTHOGONAL DRUG ACTIVATION TAGWORKS PHARMACEUTICALS B.V. (NL) 2016-04-21 — — US disclosed
US-20150344514-A1 CHEMICALLY CLEAVABLE GROUP TAGWORKS PHARMACEUTICALS B.V. (NL) 2015-12-03 — — US disclosed
US-20150344514-A1 CHEMICALLY CLEAVABLE GROUP TAGWORKS PHARMACEUTICALS B.V. (NL) 2015-12-03 — — US disclosed
US-20150297741-A1 BIO-ORTHOGONAL DRUG ACTIVATION TAGWORKS PHARMACEUTICALS B.V. (NL) 2015-10-22 — — US disclosed
US-20150297741-A1 BIO-ORTHOGONAL DRUG ACTIVATION TAGWORKS PHARMACEUTICALS B.V. (NL) 2015-10-22 — — US disclosed
WO-2014081301-A1 BIO-ORTHOGONAL DRUG ACTIVATION TAGWORKS PHARMACEUTICALS B.V. (NL) 2014-05-30 — — WO disclosed
WO-2014081300-A1 CHANNEL PROTEIN ACTIVATABLE LIPOSOMES TAGWORKS PHARMACEUTICALS B.V. (NL) 2014-05-30 — — WO disclosed
WO-2014081303-A1 CHEMICALLY CLEAVABLE GROUP TAGWORKS PHARMACEUTICALS B.V. (NL) 2014-05-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10967069-B2 Bio-orthogonal drug activation JMJD7, KIT, PAICS CYP3A4 337/4885ALDH1A1 935/4885TDP1 2839/4885
US-20150344514-A1 CHEMICALLY CLEAVABLE GROUP SQLE, CTRL, ENO1 CYP3A4 31/4885ALDH1A1 780/4885TDP1 2402/4885
US-20210162060-A1 BIO-ORTHOGONAL DRUG ACTIVATION JMJD7, KIT, PAICS CYP3A4 337/4885ALDH1A1 935/4885TDP1 2839/4885
US-20190336612-A1 BIO-ORTHOGONAL DRUG ACTIVATION JMJD7, KIT, PAICS CYP3A4 337/4885ALDH1A1 935/4885TDP1 2839/4885
US-20150297741-A1 BIO-ORTHOGONAL DRUG ACTIVATION KIT, JMJD7, TPSB2 CYP3A4 102/4885ALDH1A1 1711/4885TDP1 3134/4885
US-11857636-B2 Bio-orthogonal drug activation JMJD7, KIT, PAICS CYP3A4 337/4885ALDH1A1 935/4885TDP1 2839/4885
US-20160106859-A1 BIO-ORTHOGONAL DRUG ACTIVATION JMJD7, KIT, PAICS CYP3A4 337/4885ALDH1A1 935/4885TDP1 2839/4885
US-10376594-B2 Bio-orthogonal drug activation JMJD7, KIT, PAICS CYP3A4 337/4885ALDH1A1 935/4885TDP1 2839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.